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Abstract
Background: Sentinel lymph node spread is a crucial factor in melanoma outcome. We aimed to define the impact of
minimal cancer spread and of increasing numbers of disseminated cancer cells on melanoma-specific survival.
Methods and Findings: We analyzed 1,834 sentinel nodes from 1,027 patients with ultrasound node-negative melanoma
who underwent sentinel node biopsy between February 8, 2000, and June 19, 2008, by histopathology including
immunohistochemistry and quantitative immunocytology. For immunocytology we recorded the number of disseminated
cancer cells (DCCs) per million lymph node cells (DCC density [DCCD]) after disaggregation and immunostaining for the
melanocytic marker gp100. None of the control lymph nodes from non-melanoma patients (n = 52) harbored gp100-positive
cells. We analyzed gp100-positive cells from melanoma patients by comparative genomic hybridization and found, in 45 of
46 patients tested, gp100-positive cells displaying genomic alterations. At a median follow-up of 49 mo (range 3–123 mo),
138 patients (13.4%) had died from melanoma. Increased DCCD was associated with increased risk for death due to
melanoma (univariable analysis; p,0.001; hazard ratio 1.81, 95% CI 1.61–2.01, for a 10-fold increase in DCCD + 1). Even
patients with a positive DCCD #3 had an increased risk of dying from melanoma compared to patients with DCCD=0
(p = 0.04; hazard ratio 1.63, 95% CI 1.02–2.58). Upon multivariable testing DCCD was a stronger predictor of death than
histopathology. The final model included thickness, DCCD, and ulceration (all p,0.001) as the most relevant prognostic
factors, was internally validated by bootstrapping, and provided superior survival prediction compared to the current
American Joint Committee on Cancer staging categories.
Conclusions: Cancer cell dissemination to the sentinel node is a quantitative risk factor for melanoma death. A model based
on the combined quantitative effects of DCCD, tumor thickness, and ulceration predicted outcome best, particularly at
longer follow-up. If these results are validated in an independent study, establishing quantitative immunocytology in
histopathological laboratories may be useful clinically.
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Introduction
For melanoma staging, sentinel node biopsy has been estab-
lished to assess melanoma cell dissemination and has become the
most widely used procedure to determine the regional lymph node
status in patients with cutaneous melanoma [1,2]. Because an
evidence-based lower threshold for clinically relevant melanoma
spread could not be defined [3], the detection of isolated
melanoma cells in sentinel nodes was included in the latest
American Joint Committee on Cancer (AJCC) staging recom-
mendations [4]. However, the prognostic value of small tumor
deposits in sentinel nodes is not unanimously accepted [5–7]. One
potential reason for this lack of confidence may be that, unlike
measurements of primary tumor thickness, highly sensitive
methods for precise and direct quantification of sentinel node
involvement by histopathology, optimal sample preparation, and
screening are still lacking. The chance of detecting rare tumor cells
by histopathology depends on the number of sections screened [8],
and extensive histopathological protocols [7,9–11] can achieve a
detection rate of 30% but require the analysis of 24 to 36 slides per
node [7]. Since this translates into 42 h of examination time for
about ten melanoma patients a week [12], it is obviously
impracticable for many institutions. Because of a lack of
standardization [7,10,11,13–16], the accuracy of sentinel node
analysis has been limited for the mentioned practical reasons.
We previously developed a quantitative immunocytological
assay to identify early cancer spread in sentinel nodes [17]. In this
assay, the sentinel node is disaggregated, and disseminated cancer
cells (DCCs) are detected by immunostaining for gp100, an
antigen involved in melanin synthesis, using the HMB45 antibody
[17]. The number of DCCs per 106 isolated cells defines the DCC
density (DCCD). In the current study we applied this assay to a
prospective cohort of 1,027 patients. The aim was to evaluate its
predictive value as a quantitative variable in comparison to
qualitative routine histopathology and to address the role of
minimal tumor seeding in the survival of melanoma patients.
Methods
Ethics Statement
Our study complied with the guidelines of the Declaration of
Helsinki. As such, the institutional review boards of the University
of Tu¨bingen (ethics vote number 5/99) and the University of
Regensburg (ethics vote number 07/79) approved the study. All
patients provided written informed consent to examination of their
sentinel nodes by disaggregation immunocytology, to the record-
ing of their follow-up data in the Central Malignant Melanoma
Registry of the German Dermatological Society, and to the
molecular characterization of the isolated cells. Control (non-
melanoma) nodes were obtained from patients with chronic
venous insufficiency in whom a lymph node was removed during
crossectomy, or from non-melanoma skin cancer patients. Sample
acquisition was in agreement with the rules of the Ethics
Committee of the University of Tu¨bingen for use of waste tissue.
No personal data were recorded from the control patients.
Patients
From February 8, 2000, to June 16, 2008, we enrolled 1,154
patients who underwent lymphatic mapping and sentinel node
biopsy at the University Hospital Tu¨bingen, Germany, for
histopathologically proven first invasive primary cutaneous mel-
anoma. At the Department of Dermatology, University Hospital
Tu¨bingen, sentinel node biopsy is generally recommended for
patients with melanoma lesions with a Breslow’s tumor thickness of
$1.0 mm, with primary tumors of Clark level IV or V, or with
tumors of any Breslow’s thickness but showing regression or
ulceration. Twelve patients without other risk factors requested
sentinel node biopsy although their melanomas were thinner than
1 mm. The preoperative staging to exclude metastatic disease
consisted of a physical examination, ultrasound examination of
regional lymph nodes and the abdomen, chest X-ray, and
computed tomography brain scans. For final analysis 119 patients
were excluded as they had a follow-up of less than 3 mo, and eight
patients were excluded because of missing information about
primary tumor thickness. The remaining 1,027 patients (Table 1)
included 322 whose DCCD results have been reported in an
interim analysis [17], however without follow-up information. Skin
draining control lymph nodes (n = 58) were obtained from 52 non-
melanoma patients (52 skin draining nodes from nonmalignant
conditions, six sentinel nodes from non-melanoma skin cancer
patients) and disaggregated, stained, and evaluated identically to
the lymph nodes of melanoma patients.
Lymphatic Mapping, Sentinel Node Biopsy, and Tumor
Cell Detection
Cutaneous lymphoscintigraphy, sentinel node biopsy, and
sample preparation were performed as previously described [17]
with minor modifications. From the beginning of the study until 31
July 2003, the procedure was as follows. The lymph node was cut
along its longitudinal axis for histopathological and immunocyto-
logical examination. One half of the sentinel node was fixed in
3.5% formaldehyde, paraffin-embedded, and subjected to stan-
dard histopathological treatment, which included hematoxylin and
eosin staining and immunohistochemistry on three 4-mm paraffin
sections from the central level. From 1 August 2003 until the end
of the study, the procedure was as follows. The lymph nodes were
cut perpendicularly to the long axis [15]. For histopathology,
2-mm slices were cut after formalin fixation of the tissue.
Hematoxylin and eosin staining and immunostaining (using
antibodies directed against S100, HMB45, and Melan-A) of
sections from each level was performed as described above. Thus,
the total number of sections examined per node varied according
to the size of the node. However, in all cases at least two levels
(with four 4-mm sections each) were examined. The complete
histopathological workup of the lymph nodes was done at the
Department of Pathology, University of Tu¨bingen, without
knowledge of the immunocytological gp100 result. A patient was
documented as histopathologically positive if at least one node was
considered positive by the histopathological examination. The
patients with isolated tumor cells were considered histopatholog-
ically positive.
Quantitative immunocytology was performed immediately after
sentinel node biopsy at the Department of Dermatology, University
of Tu¨bingen, using the other unfixed half of the lymph node [17].
The lymphatic tissue was cut into 1-mm pieces and disaggregated
mechanically into a single-cell suspension by rotating knifes (DAKO
Medimachine, DAKO), washed with HBSS (Life Technologies),
and centrifuged on a density gradient made of a 60% Percoll
solution (Amersham). Cells were counted using a Neubauer
counting chamber. Per slide, 106 cells from the interphase were
then dispensed onto adhesion slides (Menzel) in a volume of 1 ml of
PBS. After sedimentation for 1 h, the slides were air-dried
overnight. Immunocytological staining was carried out with the
alkaline phosphatase/anti-alkaline phosphatase method using
primary antibodies against gp100 (HMB45, DAKO) and Melan-
A (A103, DAKO), and 5-bromo-4-chloro-3-indolyl phosphate/
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NBT (DAKO) as substrate, yielding a blue reaction product. A
lymph node was defined as gp100 positive or Melan-A positive if it
contained at least one gp100-positive or one Melan-A-positive cell,
respectively. The number of positive cells per million isolated cells
was recorded after screening of the slides by a technical assistant and
final evaluation by a dermatologist, both experienced in evaluation
of cytological preparations. The recording was done without
knowledge of the histopathological findings or other clinical data.
Positive preparations were air-dried or stored for a maximum of 4 d
in PBS until cell isolation for genomic analyses.
gp100/Melan-A Double Staining
For double immunofluorescence staining, additional slides were
stained with primary antibodies against MART-1/Melan-A
(rabbit monoclonal IgG, Epitomics) and gp100 (clone HMB45,
mouse monoclonal IgG, DAKO). The cells were visualized after
staining with Alexa Fluor 555 (donkey anti-rabbit IgG, Invitrogen)
and Alexa Fluor 488 (donkey anti-mouse IgG, Invitrogen) and
counterstained with 49,6-diamidino-2-phenylindole (DAPI).
Single-Cell Comparative Genomic Hybridization
Single-cell comparative genomic hybridization (CGH) was
performed as previously described [18,19]. In brief, proteinase K
was used to digest cellular proteins after isolation, the single-cell
genome was digested using MseI, adaptors were ligated to the 59
overhangs, and the DNA fragments were amplified by PCR,
resulting in an MseI representation of a single-cell genome. The
reagents and protocol are now commercially available as kit
(Ampli1, Silicon Biosystems). These amplicons were labeled and
hybridized onto metaphase spreads or an Agilent 180 K
microarray for array CGH [35]. Histograms for the CGH data
were generated using the online algorithms at http://progenetix.
net [20]. Twelve of the 46 patients from whom we isolated gp100-
positive cells for the had samples with a median DCCD of 2
gp100-positive cells per million isolated cells (range 1 to 7) and
were included solely to investigate the genomes of the early DCCs.
Statistical Analyses
Melanoma-specific survival rates were calculated from the date of
sentinel node biopsy until death from melanoma or the last follow-
up. The 5-y survival percentages are derived from the Kaplan-Meier
survival estimates, F(t). The 95% confidence intervals were based on
the log(2log F(t)) transformation as described by Kalbfleisch and
Prentice [21]. We calculated Pearson’s correlation coefficient of
log(DCCD + 1) and log(Melan-A + 1) for assessing the association of
DCCD and Melan-A. For the comparison of positive DCCD values
among subgroups of the other six prognostic variables we used either
two-sample t-tests or one-way ANOVA after logarithmic transfor-
mation, i.e. we compared geometric means.
We used dot plots together with quartiles to show the differences
in the distribution of DCCD values among the groups defined by
the other variables.
We used univariable Cox regression models for the following
seven predictors: gender, age, Breslow’s thickness, ulceration,
Table 1. Baseline characteristics of study cohort.
Characteristic
Number of




Age (years) 58 10–86 44–69


















DCCD 0.5 0–950,000 0–4
aClinical stage according to the AJCC 2009 classification [4]. For nodal status only results of histopathology were taken into account. Information about mitotic rate was
not available.
doi:10.1371/journal.pmed.1001604.t001
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localization, nodal status pathology, and DCCD. A log transfor-
mation was used for the variable tumor thickness, and the
logarithm of DCCD + 1 was used for the variable DCCD; hazard
ratios are reported together with their 95% confidence intervals.
p-Values are given for the likelihood ratio tests of the Cox models.
In addition, we calculated hazard ratios after grouping of the
three continuous variables age, thickness, and DCCD. We plotted
the hazard ratios of the models with the continuous and the
grouped data for DCCD and tumor thickness in order to verify a
linear model on a logarithmic scale.
For multivariable Cox regression analyses we adopted the
model selection criterion according to Schwarz [22] and used the
minimal value of the Bayes information criterion (BIC) to select
the optimal model. This quantity is the sum of twice the negative
log likelihood of the model plus the number of parameters times
the logarithm of the sample size. Instead of evaluating the
likelihood for all 128 ( = 27) possible models we started with the
model that included all seven variables, and then successively
deleted the variable with the highest p-value. This approach finds
the model with the lowest BIC value for a given number of
variables, which was verified by calculating the BIC value for all
128 models.
For internal validation we used 100 bootstrap samples and
calculated Harrell’s c-index with and without correction for
optimism [23]. We calculated Harrell’s c-index instead of Somer’s
D because Harrell’s c-index (c= (D+1)/2) estimates the proportion
of concordant pairs among all comparable pairs of patients. We
proceeded as follows. Step 1: we determined capp from our model
as selected using the BIC criterion. Step 2: we generated 100
bootstrap samples from the original dataset by sampling with
replacement. Step 3: for each of these 100 bootstrap samples the
same model selection procedure as for the original dataset was
applied. Step 4: for each of the 100 bootstrap samples we
calculated the c-index cboot. Step 5: the 14 different models found
in step 3 were applied to the original dataset, and the
corresponding c-indices corig determined. Step 6: the average
optimism of the fit was calculated as corig2cboot. Step 7: the
bootstrap-corrected performance of the original stepwise model
was calculated as capp2(corig2cboot).
In order to verify the proportional hazards assumption of the
Cox model we divided the patients into two groups for each of the
three final predictors and plotted the ratio of their cumulative
hazard functions as a function of time. According to the Cox
model this ratio should stay constant. As an alternative to the Cox
model we used the lognormal distribution as a model for
predicting outcome by DCCD, thickness, and ulceration. The
lognormal model allows determination of the maximum time-
dependent hazard rate and the time at which it occurs (formulas
for the lognormal survival probability are in Text S1). We used the
lognormal model to determine the 5-y survival probabilities by a
nomogram [24].
Model Validation and Comparison
To assess the goodness of fit of the models (Table S3), we
divided the 1,027 patients into 18 subgroups according to the
following criteria: three groups of DCCD values, with DCCD=0
assigned the value 0, 0, DCCD ,100 assigned the value 1, and
DCCD $100 assigned the value 2; three groups of tumor
thickness, with tumor thickness #2 mm assigned the value 1,
2 mm , tumor thickness #4 mm assigned the value 2, and tumor
thickness .4 mm assigned the value 3; and ulceration no/yes. We
restricted the analysis to 18 subgroups because otherwise the
number of patients per subgroup would be too small. Only a slight
difference in the hazard ratio was observed between the categories
0, DCCD#3 and 3, DCCD,100, as shown in Table 2. These
categories were therefore combined. For each of the 1,027
patients, we calculated the expected failure probability for the
individual follow-up times. The observed numbers of deaths in the
18 subgroups were compared to the expected numbers of deaths
by the chi-square statistics. The goodness of fit of the models was
compared by the sum of the 18 chi-square values, taking into
account the number of degrees of freedom, which depends on the
number of estimated parameters. Since the models were not
nested we did not perform likelihood ratio tests. We provide the
chi-square statistics only for descriptive purposes. The grouping of
patients according to AJCC criteria was based on the AJCC 2009
recommendations (which include assignment of isolated tumor
cells as nodal positive) [4], with the exception that mitotic rate
could not be included because it had not been assessed at the
beginning of the study. For the AJCC grouping, the nodal status
was determined by histopathology and not by immunocytology.
For the parametric model with the variables thickness, DCCD,
and ulceration, each individual patient was characterized by his or
her risk score. This score was a linear combination of the
logarithms of tumor thickness and DCCD and of ulceration. The
purpose was to assess the goodness of fit of our model in four well-
defined groups of patients. Since the precision of Kaplan-Meier
estimates depends essentially on the number of deaths in a sample,
we wanted to achieve similar precision in all four groups. To this
end the 138 patients who died from melanoma were divided into
four groups with increasing risk scores of death, as defined by the
survival model. Subsequently, the risk thresholds of the four
groups were applied to all the patients. For given values of the
three variables included in the predictive models each patient can
uniquely be assigned to one of the four groups. All four groups
differed from each other significantly (all p-values ,0.001 in the
log-rank test comparing group 2 to group 1, group 3 to group 2,
and group 4 to group 3).
We next compared the goodness of fit of the parametric model
with the variables thickness, DCCD, and ulceration with a Cox
model using the same variables. We found that the parametric
model performed better (p = 0.13, sum of x2 values = 21.1) than
the corresponding Cox proportional hazards model (p = 0.03, sum
of x2 values = 27.4) after grouping all 1,027 patients into the 18
risk groups (see above and Table S3).
To assess whether a model that included the information on
Melan-A staining in addition to gp100 staining could further
improve outcome prediction we compared our model based on
DCCD (the maximum number of gp100-positive cells per million
isolated cells per patient), thickness, and ulceration with the model
DCCD 2 (defined as the maximum number of gp100- or Melan-
A-positive cells per million isolated cells), thickness, and ulceration.
We found that the model that included the information on
Melan-A staining was not superior to gp100-based DCCD
reporting (p = 0.09, sum of x2 values = 22.7; Table S3). Finally,
we compared the predictions based on our parametric model and
on AJCC staging [4]. The goodness of fit for our model (p = 0.13,
sum of x2 values = 21.1) was much better than that of the AJCC
staging model (p,0.0002, sum of x2 values = 36.7). For details and
data, see the Table S3.
For comparison with the AJCC model, the patients were
originally divided into three groups according to the differences in
survival predictions between the two models. For individuals in
Group S1 of Table S2, the survival probability for the new model
was at all times greater than the survival probability according to
the AJCC model; the absolute percentage difference was greater
than 13%. In Group S2 the survival probability for the new model
was at all times smaller than the survival probability according to
Quantification of Melanoma Spread and Survival
PLOS Medicine | www.plosmedicine.org 4 February 2014 | Volume 11 | Issue 2 | e1001604
the AJCC model; the maximum absolute percentage difference
was greater than 13%. For Groups S1 and S2, the maximum
absolute percentage difference of 13% was chosen because it
exceeds the maximum absolute percentage differences for those
patients for whom the survival in one model was not always
greater than the survival in the other model. The remaining
patients formed Group S3.
The risk scores were the sums of the products of the individual
predictors multiplied by the corresponding regression coefficients.
Since some tumor thicknesses were less than 1 mm, we also
obtained negative risk scores because tumor thickness was on a log
scale.
We performed statistical analyses with JMP (version 10.0.2).
Results
Patients
The final analysis included a total of 1,834 sentinel nodes from
1,027 patients examined by quantitative immunocytology and by
histopathology. The baseline characteristics of all 1,027 patients
are summarized in Table 1. The median follow-up was 49 mo
(range 3 to 123 mo), with 370 (36%) patients having a follow-up of
at least 5 y. During follow-up, 138 of 1,027 patients (13.4%) died
from melanoma. The 5-y melanoma-specific survival probability
for all patients was 86% (95% CI 83%–88%).
Detection of Disseminated Melanoma Cells by
Immunocytology
The underlying rationale of our detection assay (Figure 1A–1E)
comprises two aspects. First, the spatially inhomogeneous distri-
bution of melanoma cells may be equalized by lymph node
disaggregation and generation of a single-cell suspension, which
facilitates melanoma cell detection when only parts of the sample
are screened; second, the number of melanoma cells can be
counted and the amount of analyzed tissue can be quantified by
referencing the number of melanoma cells to a defined number of
isolated lymph node cells. This allows determining the DCCD, i.e.
the number of DCCs per 1 million isolated cells.
We first assessed whether gp100-positive cells could be detected
in skin draining nodes from non-melanoma patients. These lymph
nodes were prepared identically to the sentinel nodes from
melanoma patients (Figure 1B–1D), except that lymph nodes from
cancer patients had to be split in half to provide tissue for routine
histopathology. We could not detect a single gp100-positive cell
among 1716106 cells isolated from 58 non-melanoma skin
draining lymph nodes.
Table 2. Univariable survival analyses.
Variable
Number of
Patients Median (Range) Hazard Ratioa 95% CI p-Value
Gender
Female 449 1
Male 578 1.43 0.95–1.89 0.10
Age 58 (10–86) y 1.02 1.01–1.04 ,0.001
,58 y 508 1
$58 y 519 1.79 1.28–2.54 ,0.001
Breslow’s thickness 1.85 (0.24–20.00) mm 18.63 10.68–32.24 ,0.001
#2.00 mm 579 1.30 mm 1
2.01–4.00 mm 315 2.75 mm 2.89 1.91–4.42 ,0.001
4.01–8.00 mm 106 5.00 mm 6.78 4.26–10.76 ,0.001
$8 mm 27 10.00 mm 11.66 5.81–21.73 ,0.001
Ulceration
No 738 1
Yes 289 3.79 2.71–5.32 ,0.001
Localization
Extremities 500 1
Trunk or head 527 1.43 1.02–2.02 0.04
Nodal status pathology
Negative 888 1
Positive 139 4.34 3.04–6.11 ,0.001
DCCD 0.5 (0–950.000) 1.81 1.61–2.01 ,0.001
DCCD= 0 502 0 1
0, DCCD #3 249 1 1.63 1.02–2.58 0.041
3, DCCD ,100 194 9 1.66 1.01–2.68 0.048
100# DCCD 82 1,081 8.04 5.13–12.60 ,0.001
aIn addition to the hazard ratios for the groups we also provide unit hazard ratios for the continuous variables age, tumor thickness, and DCCD, together with their
p-values. Tumor thickness and DCCD + 1 enter the Cox model with their common logarithms; thus, a unit corresponds to a 10-fold increase. For thickness, a unit
corresponds to an increase from 1.3 to 13 mm. For DCCD a unit corresponds to an increase from zero to nine cells, because we add one to all cell counts before taking
logarithms.
doi:10.1371/journal.pmed.1001604.t002
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On the other hand, we detected gp100-positive cells in the
lymph nodes of 525 of the 1,027 melanoma patients (51%).
Whenever enough cells were isolated from the lymph node half for
immunocytology, we aimed to screen 26106 lymph node cells, i.e.,
two slides, per patient. The median number of slides screened per
node was two (range 104 to 66106 cells). The median DCCD in
patients with DCCD .0 was 4 gp100-positive cells per million
isolated cells (ranging from 0.2 to 950000; Figure 1F). We
evaluated the relation of DCCD with the six established prognostic
factors (Figure 2). Geometric mean values of DCCD were
significantly higher in thicker and ulcerated melanomas (p,
0.001), in melanomas located at other sites than the extremities
(p = 0.02), and in patients with a pathologically positive sentinel
node (p,0.001; Figure 2).
However, severe concerns about the immunocytological assay
may be raised by (1) the loss of architectural information, which
helps to differentiate between intra-lymphatic nevi and colonies of
melanoma cells, (2) the difficulty to identify melanoma colonies by
morphological criteria, and (3) the fact that the gp100 antigen for
melanoma detection may be down-regulated. We addressed these
concerns by careful evaluation of lymph node preparations from
melanoma and non-melanoma patients using a second melanoma-
associated antibody directed against Melan-A and by genetic
analysis of the gp100-positive cells.
We found Melan-A-expressing cells in three out of 38 (8%)
control lymph nodes, all of which were gp100 negative. We then
proceeded to determine the detection rate of the two antibodies for
melanoma cells in sentinel nodes from melanoma patients with
histopathologically proven lymphatic spread by applying a double
staining method. Because Melan-A-positive cells were detected in
8% of control nodes, we restricted the direct comparison of gp100-
and Melan-A-positive cells to samples from histopathologically
Figure 1. Sample preparation, melanoma cell detection, and distribution of disseminated cancer cell densities. (A) The sentinel nodes
were split into halves for routine histopathology and immunocytology. (B–D) After mincing (B), the small pieces were subjected to mechanical
disaggregation (C), and single-cell suspensions were added to adhesion slides (D). (E) The detection of gp100-positive cells among the unstained
lymphocytes. (a) gp100 staining of Mel Ho cell line cells mixed among peripheral blood leukocytes used as positive control. (b) Isotype control of
positive control. Note that the large melanoma cells can be identified by size among the peripheral blood leukocytes and are completely unstained.
(c) gp100-positive cell from melanoma patient with DCCD= 1. (d) Isotype control of the melanoma patient in (c). All four samples are taken from the
same experiment. (F) The distribution of DCCD (number of DCCs per 106 isolated cells) in the sentinel nodes of 525 gp100-positive patients. Note that
some patients had DCCD ,1. The 502 zero values for DCCD are not included.
doi:10.1371/journal.pmed.1001604.g001
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Figure 2. DCCD and standard clinical prognostic factors. For all panels, the red lines indicate the medians, and the black lines the 25th and
75th percentiles. (A) All DCCD values are plotted according to the T stage of the primary melanoma. (B) DCCD and ulceration state of the primary
melanoma. (C) DCCD and status according histopathological routine analysis of the other lymph node half. (D) DCCD and localization of the primary
melanoma. (E) DCCD and age category (,58 y and $58 y) of patient. (F) DCCD and gender of patient.
doi:10.1371/journal.pmed.1001604.g002
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positive nodes, where expression of Melan-A by benign cells would
be less likely to confound the analysis. Evaluating 3,055 cells from
43 nodes of 41 patients after immunofluorescence double staining,
we found that 39 of 43 (91%) lymph nodes harbored cells positive
for gp100 and Melan-A (Figure S1), one of 43 (2%) had only
gp100-positive cells, and three of 43 (7%) had only Melan-A-
positive cells.
These data suggest that the slightly higher detection rate of the
Melan-A antibody does not outweigh the lower specificity as
determined by the control samples. However, to completely rule
out that gp100-negative DCCs comprise a relevant confounding
factor, additional slides were stained using the Melan-A antibody
in 710 patients. Comparing the gp100 and Melan-A staining
results of these 710 patients, we confirmed the high correlation of
gp100 and Melan-A staining (r=0.83, p,0.001) that we had
previously seen by double immunofluorescence. As detailed in
Table S3, we found that the inclusion of Melan-A did not improve
the prognostic power of the gp100-based immunocytological
assay.
Genetic Characteristics of Disseminated Melanoma Cells
Since all these findings provided indirect support that gp100-
positive cells represent DCCs, we searched for direct evidence of
their malignant origin. We randomly isolated 65 gp100-positive
cells from 46 patients for a whole-genome screen of chromosomal
aberrations by CGH. The DCCD values of these patients ranged
from 0.2 to 800,000 gp100-positive cells per million isolated cells
(median = 8), and we analyzed between one and three cells per
patient. Metaphase CGH provided direct proof for the malignant
origin of 57 gp100-positive cells (Figure 3A), while eight cells
displayed normal karyotypes. As metaphase CGH has a resolution
of 10–20 Mb, we subsequently applied array CGH [35], which
has a resolution of,1 Mb, to these eight cells. While we could not
detect any aberration in two cells, the remaining displayed
between one and ten changes (median = 4.5) ranging from 0.1 to
19 Mb (median= 2 Mb). In summary, 63 of 65 gp100-positive
cells (97%) displayed genomic aberrations, which classified 45 of
46 patients (98%) as harboring cancer cells in their sentinel nodes.
There was no difference for cells isolated from lymph nodes
classified as negative or positive by routine histopathology,
demonstrating that our assay is suited to correctly identifying
melanoma cells without morphological assessment of tissue
architecture (Figure 3B).
Disseminated Cancer Cell Density and Melanoma-Specific
Survival
We evaluated DCCD as biomarker according to the REMARK
criteria [25]. Of the standard prognostic factors, sentinel node
histopathology (p,0.001), age (p,0.001), thickness (p,0.001),
ulceration (p,0.001), and localization of the primary melanoma
(p = 0.04) were associated with poor outcome in the univariable
Cox regression analyses (see Table 2 and Figure S2 for Kaplan-
Meier estimates). Increasing DCCD values were negatively
associated with the time to death from melanoma in the
univariable Cox regression analyses (p,0.001). We assessed the
prognostic impact of DCCD after categorizing the values into four
groups (Table 2). We found that even the detection of low DCCD
values (0,DCCD #3) conferred a significant risk of death (hazard
ratio 1.63, 95% CI 1.02–2.58, p = 0.04; Table 2 and Figure 4A)
compared to patients without DCCs. Increasing hazard ratios
were obtained for categories with higher DCCD values (Table 2).
The relationship of increasing DCCD values and the hazard ratio
Figure 3. Chromosomal aberrations of isolated gp100-positive cells. (A) CGH profiles of gp100-positive cells (n= 57 cells, all displaying
chromosomal aberrations in metaphase CGH). The histogram displays the percentage of cells with specific chromosomal alterations. The
chromosomal position is indicated by the horizontal chromosome ideogram (from Chromosome 1 on the left to the X and Y chromosomes on the
right). Copy number gains for each region are depicted in green, and copy number losses are depicted in red. (B) Summary of findings for all 65 cells
and 46 patients with respect to the lymph node status as determined by routine histopathology (N0= histopathologically negative nodes,
N1= histopathologically positive nodes). After analysis of the eight cells with normal karyotypes in metaphase CGH by array CGH, all but two cells
displayed genomic aberrations. One of these two cells was isolated from a sample where an additional gp100-positive cell displayed alterations, while
the other cell was the only gp100-positive cell detected in that patient.
doi:10.1371/journal.pmed.1001604.g003
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is plotted in Figure 4B on the logarithmic scale. The unit risk ratio
(corresponding to a 10-fold increase of DCCD + 1, e.g., from a
DCCD of zero to a DCCD of nine) was 1.81 (95% CI 1.61–2.01),
and a linear relation (on log scale) between DCCD and hazard
ratio was identified (Figure 4B). A similar log-linear relationship
was seen between tumor thickness and hazard ratio (Figure 4C).
We next performed stepwise multivariable Cox regression
analysis starting with all six standard prognostic factors in addition
to DCCD. After each step of the multivariable analysis the
variable with the highest p-value was deleted (Tables 3 and 4). To
identify the optimal model, we determined the BIC, which has a
minimal value for the best model [22]. As can be seen from
Table 4, the BIC value is lowest for the combined variables tumor
thickness, DCCD, and ulceration, for which all p-values were
below 0.001. The unit hazard ratios for this model were 6.96 (95%
CI 3.61–13.28) for thickness, 1.43 (95% CI 1.27–1.61) for DCCD,
and 2.04 (1.4–2.97) for ulceration. It should be noted that nodal
status determined by routine histopathology had a maximum
hazard ratio of 1.75 (95% CI 1.04–2.86) in multivariable analyses
and was rejected already in step 3 (Table 3).
Individual Risk Prediction by Tumor Thickness,
Disseminated Cancer Cell Density, and Ulceration
To fully exploit the power of our quantitative assay, we
combined the three most important risk factors identified by
multivariable analysis (tumor thickness, DCCD, and ulceration)
for individual risk assessment at diagnosis and during follow-up.
While results of Cox models represent a useful summary for the
average hazard ratios, we observed that the assumption of
proportional hazards was not fulfilled for tumor thickness and
DCCD (Figure S3). Therefore, we employed a lognormal survival
model based on tumor thickness, DCCD, and ulceration that
allows the calculation of changes in individual risk over time and of
the predicted 5-y survival for all 1,027 patients (Figure 5A).
Figure 5A shows that patients with thin melanomas never
harbored high DCC numbers in their lymph nodes and poorest
outcome was seen for thick tumors and high DCCD. It should be
noted that DCCD and tumor thickness are plotted on a
logarithmic scale, and therefore the curves of equal 5-y survival
probability appear as straight lines. On a linear scale these curves
(isoboles) are convex (Figure S4), which indicates synergism [26].
Using this model, we calculated the time-dependent hazard rates
for 14 individual patients with five different hazard rate curves
(Figure 5B). This calculation revealed that DCC-negative and
DCC-positive patients might display identical hazard rate
functions (e.g., compare Patients 2a and 2b in Figure 5B) and
also that the hazard rate peaks later in low-risk than in high-risk
patients. Furthermore, tumor thickness, DCCD, and ulceration
state can be integrated into a preliminary nomogram to determine
the 5-y survival of individual patients (Figure 5C).
Figure 4. The prognostic impact of disseminated cancer cells in
sentinel nodes. (A) The figure shows the Kaplan-Meier survival
estimates for 502 patients with DCCD=0 (blue line) and for 249 patients
with 0, DCCD #3 (red line). Even patients with low numbers of DCCs
had a significantly reduced survival in comparison to patients without
DCCs (86% 5-y survival versus 92% 5-y survival; hazard ratio 1.63, 95%
CI: 1.02–2.58). (B) Hazard ratios (in black) for the three DCCD categories
of Table 2 together with their 95% confidence intervals as a function of
their median DCCD values on a log scale. The red line provides the
hazard ratios for the linear model where log(DCCD + 1) is entered as a
continuous variable. The predicted curve is within the confidence
intervals. The unit risk ratio 1.81 is the hazard ratio corresponding to a
10-fold increase of DCCD + 1. (C) Relation of Breslow’s thickness and risk
of death from melanoma. Hazard ratios (in black) are given for the three
groups of Table 2 (melanomas with 2 mm # tumor thickness #4 mm;
4, tumor thickness #8 mm; tumor thickness .8 mm) together with
their 95% confidence intervals as a function of their median thickness
values on a log scale. The red line shows the predicted hazard ratios for
the model where log(thickness) enters as a continuous variable. We
show only the values $1.3 mm, i.e., the median value of the reference
group in Table 2. The predicted line is within the confidence intervals.
The unit hazard ratio 18.6 corresponds to a 10-fold increase of
thickness.
doi:10.1371/journal.pmed.1001604.g004
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Internal Validation of the Model
While the present survival model based on the predictors
thickness, DCCD, and ulceration awaits validation by an
independent multi-center study, we sought to validate it internally.
For this we applied a bootstrapping approach [23]. We generated
100 bootstrap samples from the original dataset by sampling with
replacement. For each of these 100 bootstrap samples the same
model selection procedure as for the original dataset was applied.
We obtained 14 different ‘‘best models’’ (Table 5). The present
model was selected most often. The variable DCCD was included
in 85 best models, whereas nodal status by routine histopathology
was included in only 36 of the 100 models. Harrell’s c-index, which
estimates the probability of concordance between predicted and
observed responses, for the present model was 0.763 in the original
dataset. Harrell’s c-index based on the current AJCC staging
system was 0.737. This is significantly smaller (p,0.0001;
McNemar’s test). The bootstrap-corrected c-index [23] for the
present model turned out to be 0.748, which is well above the
value of 0.5 representing only random prediction ability.
We then analyzed those patients for whom the predictions of the
AJCC and the new model differed (survival probability in group
S1: new model . AJCC; in group S2: new model , AJCC; group
S3, remaining patients). We calculated the expected number of
deaths at the observed follow-up time for each patient and
compared this number with the observed number of deaths (Table
S2). Only the new model provided an acceptable fit for all three
groups. In Group S2 of Table S2 the number of deaths predicted
in the AJCC model was significantly different from the number of
observed deaths (p,0.0001).
Finally, we combined Groups S1 and S3 from Table S2 to form
two groups. Group 1 now comprised patients for whom the novel
model predicted better survival than the AJCC model and patients
for whom the predictions of both models concurred. Patients for
whom the novel model predicted a worse survival than the AJCC
model formed Group 2.
Nearly 94% of AJCC low-risk patients (,IIB) were in Group 1
(Figure 6A and 6B). Nearly 29% of AJCC high-risk patients (.IIA)
were in Group 2. Patients in Group 2 had higher DCCD values than
patients in Group 1. The geometric means of DCCD + 1 are 2.23
(95% CI 1.98–2.51) in Group 1 and 80.53 (95% CI 59.54–108.94) in
Group 2, respectively (p,0.0001; two-sample t-test for the logarithms).
For the time points 3 and 6 y after sentinel lymph node biopsy
we determined which model provided a better fit for the survival of
patients in Group 1 and 2. Kaplan-Meier plots demonstrated that




in Model Breslow’s Thicknessa DCCDb Ulcerationc Aged Nodal Statuse Localizationf Genderg
1 7 6.51 (3.32–12.58) 1.25 (1.06–1.46) 1.89 (1.30–2.76) 1.02 (1.01–1.03) 1.74 (1.03–2.85) 1.32 (0.91–1.93) 1.05 (0.73–1.52)
2 6 6.46 (3.31–12.45) 1.24 (1.06–1.46) 1.89 (1.30–2.76) 1.02 (1.01–1.03) 1.75 (1.04–2.86) 1.34 (0.94–1.92) —
3 5 6.09 (3.11–11.77) 1.29 (1.11–1.50) 1.90 (1.31–2.78) 1.02 (1.00–1.03) 1.67 (1.01–2.72) — —
4 4 6.63 (3.42–12.71) 1.43 (1.27–1.60) 1.94 (1.33–2.84) 1.01 (1.00–1.03) — — —
5 3 6.96 (3.61–13.28) 1.43 (1.27–1.61) 2.04 (1.40–2.97) — — — —
6 2 10.75 (5.86–19.54) 1.47 (1.31–1.65) — — — — —
7 1 18.63 (10.68–32.24) — — — — — —
alog10 of tumor thickness;, hazard ratios for a 10-fold increase.
blog(DCCD + 1); hazard ratios for a 10-fold increase.
cHazard ratios for ulceration versus no ulceration.
dHazard ratios for one additional year.
eHazard ratios for positive versus negative by routine histopathology.
fHazard ratios for trunk or head versus extremities.
gHazard ratio for male versus female.
doi:10.1371/journal.pmed.1001604.t003






Thickness DCCD Ulceration Age
Nodal
Statusa Localization Gender BIC
1 7 ,0.0001 0.0068 0.0009 0.0051 0.0371 0.1380 0.8052 1,657.8
2 6 ,0.0001 0.0069 0.0008 0.0050 0.0340 0.1035 — 1,650.9
3 5 ,0.0001 0.0011 0.0008 0.0054 0.0475 — — 1,646.6
4 4 ,0.0001 ,0.0001 0.0005 0.0127 — — — 1,643.6
5 3 ,0.0001 ,0.0001 0.0002 — — — — 1,642.9
6 2 ,0.0001 ,0.0001 — — — — — 1,649.8
7 1 ,0.0001 — — — — — — 1,679.1
p-Values are for testing whether a hazard ratio equals 1; low BIC identifies best model.
aAs determined by routine histopathology.
doi:10.1371/journal.pmed.1001604.t004
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Figure 5. Individualized risk estimation over time. (A) The predicted 5-y survival by DCCD, tumor thickness, and ulceration for all 1,027
patients. Dots indicate patients who were alive at the end of follow-up; circles indicate patients who died from melanoma (n= 138). The red symbols
indicate patients with ulcerated melanomas. The patients left of the vertical line at DCCD + 1= 1 (n=502) displayed no DCCs in their sentinel nodes.
Dots located on the same continuous line represent patients with the same 5-y survival, which is depicted at the right end of the lines (red lines for
the patients with ulcerated melanoma). For example, for Patient 1 and Patient 5 from (B) (circled in blue), the estimated 5-y survival of Patient 1 is .
99.5%, while for Patient 5 it is about 6%. The parametric survival model is based on the lognormal distribution and includes DCCD, thickness, and
ulceration. (B) Time-dependent hazard rates for 14 individual patients with five different hazard rates (1–5) with their observed thickness, DCCD, and
ulceration status, and their corresponding predicted 5-y survival rates and median survival times. Different combinations of thickness, DCCD, and
ulceration status may indicate the same risk of death from melanoma. In contrast to the Cox model, the predicted hazard ratios vary over time. (C) A
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the predicted and observed survival curves diverge particularly for
the AJCC prediction of Group 2 patients (Figure 6C). For both
time points 3 and 6 y (p,0.001 and p,0.01, respectively) the
AJCC model significantly deviated from Kaplan-Meier estimates
for Group 2 patients, whereas our model correctly predicted the
number of deaths (Table 6).
For the low-risk patients of Group 1, both models provided
acceptable fits, although we noted a borderline p-value (p=0.06)
for the new model at 3 y. However, the fit for predicted and
observed survival becomes excellent for the new model over time
(Figure 6C)—in line with the need for longer observation periods
in low-risk patients. Thus, at 6 y follow-up there is perfect
agreement for the new model, whereas the AJCC model
overestimates the number of deaths (Figure 6C and Table 6).
We assessed the goodness of fit of the model after grouping the
patients according to their risk scores, which was a linear
combination of the logarithms of tumor thickness and DCCD
and of ulceration, into four groups (see Methods). We compared
predicted and observed survival curves and found that Kaplan-
Meier curves and predicted curves were superimposable over the
complete range of disease courses for all four risk groups and that
all four groups differed significantly from each other (Figure 7).
Finally, we compared the goodness of fit for several models (a
model based on Cox regression analysis, a model that includes
data on Melan-A staining, and a model based on the current
AJCC criteria). In summary, we found that the parametric model
based on thickness, DCCD, and ulceration most accurately
predicted melanoma death (Table S3).
Discussion
In this study, we quantified the number of DCCs per one
million isolated lymph node cells (DCCD) and assessed its utility in
predicting melanoma outcome. Based on a median follow-up of
49 mo, with 370 patients having follow-up times of more than 5 y,
we found that at the time of sentinel node biopsy, quantitative
assessment of DCCD predicted melanoma outcome by univariable
and multivariable analysis in a large cohort of patients. Further-
more, quantitative DCCD showed a stronger association with
outcome than qualitative conventional histopathology and, when
combined with primary melanoma thickness and ulceration, had a
synergistic impact on patient survival. Using these variables we
developed a parametric model that proved to be the most accurate
for predicting outcome. Although we currently lack an external
validation cohort with long follow-up, the accepted prognostic role
of sentinel lymph node spread [4] and the successful internal
validation (bootstrap and goodness of fit) give credibility to the
findings.
We found that even the detection of three or fewer DCCs per
million leukocytes in the sentinel node increases the risk of death at
5 y from melanoma by 6% (8% for DCCD=0 versus 14% for
0, DCCD #3). This finding is in line with reports supporting the
clinical relevance of single DCCs [5,27] and the novel AJCC
recommendation [4] to refrain from using a lower threshold for
sentinel node spread. However, we also identified three
shortcomings of the AJCC categorization approach. First, AJCC
staging does not differentiate between isolated cancer cells and
small and large microscopic metastases. Our data demonstrate
that the number of cells matters over the full range of DCCD.
Second, because any measured DCCD value can be translated
into a 5-y survival rate, the typical exaggerations of categorizing
staging systems, such as upgrading from stage II to stage III
because of the detection of a single melanoma cell, are also
avoided, and individual disease courses can be accommodated
better than by categorizing tumors based on the AJCC staging
system. Third, we provide clinical evidence for the context
dependency of the metastasis-forming potential of DCCs, which
emerges from our observation that DCCD, tumor thickness, and
ulceration—being the leading prognostic factors from the multi-
variable analysis—can be combined in a parametric survival
model where the prognostic value of a single DCC differs for thick
and thin tumors. For example, we observed DCCs in 46% of T1
stage melanomas; however, 5-y survival rates are more than 90%
in this subgroup of patients, indicating that under most conditions
DCCs do not result in clinically relevant metastasis. This may
suggest that cellular programs such as senescence or dormancy are
activated at initial homing to distant sites [28,29] but may be
released once primary tumors grow large. Such a scenario has
gained credibility since secreted factors of primary melanomas,
such as exosomes, were shown to evoke substantial systemic effects
[30] promoting metastasis.
In addition to DCCD and thickness of the primary melanoma,
ulceration status had an impact on survival in melanoma. The
biological interdependencies between destructive growth (ulcera-
tion), tumor-mass-induced systemic alterations (tumor thickness),
and metastatic dissemination (DCCD) for progression of an
individual melanoma may explain why histopathologically node-
positive patients can have a better outcome than histopatholog-
ically node-negative patients if the primary melanoma has more
favorable prognostic features. This phenomenon is not reflected
within a categorizing staging system. For example, the current
AJCC staging predicts a 5-y survival of 53% for stage IIC
(T4bN0M0) and 70% for stage IIIa (T1-4N1aM0). In contrast, the
estimated survival of a patient with tumor thickness 7.4 mm and
DCCD=0 but without ulceration is identical to the estimated
survival of a patient with ulceration and tumor thickness 3.35 mm
and DCCD=2, or with tumor thickness 1.2 mm and
DCCD=772 in our model.
Since summary measures of survival may provide insufficient
information about population dispersion, we asked whether the
new model reflects the prognostic heterogeneity of patients more
accurately. Indeed, we identified a group of patients at high risk for
progression in whom the AJCC model underestimates the risk of
death. Although this group of patients is relatively small (13% in
our cohort), these patients will most likely benefit from adjuvant
therapy, and the model may help to improve patient stratification
for clinical trials. It also identified a group of very low risk patients
who have an excellent long-term outcome and whose risk of dying
is overestimated by the AJCC staging model.
We carefully evaluated the performance of our assay. As lymph
node disaggregation destroys the tissue architecture, some
morphological criteria to identify melanoma cells are lost.
However, we deem it unlikely that benign nevus cells in sentinel
nodes, described in up to 28% of melanoma patients [9], confound
our conclusions. These cells rarely express gp100 [31], and
nomogram enables estimating the 5-y survival probability. The 5-y survival probability is the value at the intersection of a straight line connecting
DCCD and tumor thickness with the central straight line. For illustration, the blue lines exemplify the same Patients 1 and 5 that are marked in (A) and
described in (B). Patient 5 had an ulcerated melanoma, and therefore the red scale must be used, while Patient 1 had a non-ulcerated melanoma, so
survival probability is given on the black scale. Note that the nomogram has not been independently validated and therefore is not yet suitable for
clinical use.
doi:10.1371/journal.pmed.1001604.g005
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likewise we could not find gp100-expressing cells in non-
melanoma lymph nodes. While this does not rule out the
possibility that truly DCC-negative sentinel nodes from melanoma
patients may contain gp100-expressing benign nevus cells, our
finding that even low numbers of gp100-positive cells are
prognostically relevant would then suggest that gp100-positive
nevus cells may be prognostically informative. Furthermore, in
97% of all analyzed gp100-positive cells we detected chromosomal
or subchromosomal alterations. For only one patient out of 46
could we not confirm the malignant descent of the isolated cell. In
all other cases genetic alterations in gp100-positive cells proved
disseminated melanoma, suggesting that morphological criteria for
DCC identification are dispensable.
Then, we directly addressed the question of whether staining for
another antigen (Melan-A) increases the detection rate and the
prognostic power of the gp100-based immunoassay. However,
while Melan-A staining added a few samples (7%) to the gp100-
identified positive lymph nodes, it also stained 8% of control
nodes. Moreover, assessing the prognostic power of the combined
results of gp100 and Melan-A staining for 710 patients, we found
that the gp100-only model was more accurate.
Compared to our assay, evaluation of sentinel nodes by
pathology has two major limitations. First, sensitivity largely
depends on the number of slides examined. Second, quantification
of lymphatic melanoma spread—a three-dimensional and often
multilocular process—is impossible by histopathology. We re-
solved these problems by homogenizing the patchy spatial
distribution of tumor cells within the node [32]—which greatly
impacts detection in tissue sections but less so in our approach—
and counting the stained cells. Thus, screening of a median of only
two slides (26106 cells) per node revealed a detection rate of 51%,
whereas pathology was positive in only 14% of patients. To
achieve a similar sensitivity by histopathology, it has been
suggested that more than 36 slides per sample need to be
analyzed, indicating that immunocytology might be advantageous
also for practical reasons [7,12]. In the future, both lymph node
preparation and screening may even be subjected to partial
automation and thereby decrease workload further.
The high detection rate of immunocytology is reminiscent of the
sensitivity of RT-PCR methods, which is also around 50% [33].
However, despite 20 y of clinical evaluation, RT-PCR assays have
failed to become clinical routine. Since one of our major findings
consists in the quantitative impact of lymphatic cancer cell
dissemination for patient outcome, we deem the non-quantitative
nature of RT-PCR assays and the failure to prove the malignant
melanoma origin of the detected nucleic acids to be a likely
explanation for its failure. RT-PCR assays do not measure cell
numbers but transcript numbers, which may be generated by a
few high-expressing cells or many low-expressing cells. Since the
unit of selection during malignant progression is a cell and not a
transcript, even quantitative transcript information will always
represent a qualitative assessment of cancer spread. Therefore,
Figure 6. Differences in survival prediction between this
study’s model and the AJCC-based model. (A) Joint distribution
of the individual risk scores for the 1,027 patients according to two
predictive survival models: (1) ‘‘Risk new model’’ refers to the lognormal
model with the predictors tumor thickness, DCCD, and ulceration; (2)
‘‘Risk AJCC model’’ refers to a lognormal model based on the seven
categories of the AJCC classification (stage IA, IB, IIA, IIB, etc.). The risk
scores are sums of products of the individual predictors multiplied with
the corresponding regression coefficients. (Since some tumor thick-
nesses are less than 1 mm we obtain also negative risk scores because
tumor thickness enters on a log scale.) The area of the bubbles is
proportional to the number of patients with identical combinations of
risk values. The largest bubble contains 30 patients. The smallest
bubbles represent one patient each. In Group 2 (red; n= 136) the
survival probability for a patient from the new model is at all times
smaller than the survival probability according to the AJCC model. The
remaining patients form Group 1 (blue; n= 891). Note that there are
only seven risk groups for the AJCC model, while the new model
exploits the full risk range. (B) Observed (red filled circles; together with
the exact 95% confidence intervals) and fitted percentages of patients
in Group 2. Almost 29% of patients with AJCC stage . IIA are in Group
2, whereas only about 6% of patients with AJCC stage , IIB are in
Group 2. (C) Observed (Kaplan-Meier survival estimates; step functions)
and predicted survival probabilities for the new model (continuous
lines) and the AJCC model (dashed lines) for the Group 1 (blue) and
Group 2 (red). Note the large difference between the AJCC model and
the new model for Group 2 and the perfect fit of the observed survival
and the new model’s predictions for Group 1 after 60 mo.
doi:10.1371/journal.pmed.1001604.g006
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RT-PCR methods are unable to provide the information delivered
here that the prognostic weight of a single disseminated melanoma
cell is context dependent.
In summary, we provide evidence that quantification of
lymphatic cancer cell dissemination is feasible and can be
combined with other quantitative and qualitative characteristics
of the primary tumor for accurate individual outcome prediction,
probably not only for melanoma but also for other types of solid
cancer [34]. It will be important to validate the findings in an
independent study before the assay and the prediction model are
used clinically.
Supporting Information
Figure S1 gp100 and Melan-A double staining. Detection
of a double-positive melanoma cell in the sentinel lymph node
(gp100/HMB45, green; Melan-A, red; nuclear DAPI, blue). The
right panel shows an overlay of the three images.
(TIF)
Figure S2 Prognostic factors and melanoma survival.
The Kaplan-Meier curves for the standard prognostic factors and
grouped DCCDs.
(TIF)
Figure S3 Hazard ratios of tumor thickness, DCCD,
and ulceration over time for Cox and lognormal models.
The ratio of two cumulative hazard functions is plotted as a
function of follow-up time for the three predictive variables
DCCD, tumor thickness, and ulceration. For DCCD we
compared DCCD .0 with DCCD=0. For tumor thickness we
compared tumor thickness .1.85 mm ( =median tumor thick-
ness) with tumor thickness #1.85 mm. For ulceration we
compared positive with negative outcome. For each of the three
variables we calculated the empirical ratios of the cumulative
hazard functions as 2log(Kaplan-Meier survival), depicted as
green step functions. The blue lines show the constant hazard
ratios obtained from the corresponding Cox models. The red
curves show the ratios of the cumulative hazard functions of the
corresponding lognormal parametric survival model. There is
clear evidence for DCCD and tumor thickness that the observed
ratios of the cumulative hazard functions depart from a constant
value. They show a steady decline over the whole follow-up
period of more than 10 y.
(TIF)
Figure S4 Synergism between tumor thickness and
DCCD for outcome prediction. 5-y survival probability
(percent) as a function of tumor thickness and DCCD for all
patients without ulceration (blue isoboles) and with ulceration (red
isoboles) on a linear scale. Convex isoboles indicate synergism.
(TIF)
Table 6. Kaplan-Meier estimates versus predicted deaths for a follow-up of 3 and 6 y by model and group.
Year of
Follow-Up Group n (Percent) Expected Deaths p-Value
AJCC New Model
Kaplan-Meier
Estimates AJCC Modela New Modela
3 1 891 (86.8) 61.9 45.8 58.6 0.67 0.06
3 2 136 (13.2) 19.1 33.0 32.8 0.001a 0.97
6 1 891 (86.8) 145.1 124.0 123.0 0.07 0.93
6 2 136 (13.2) 39.2 58.0 55.0 0.01a 0.69
aCompared to Kaplan-Meier estimates.
doi:10.1371/journal.pmed.1001604.t006
Figure 7. Goodness of fit of observed and predicted survival
for four risk groups. The 138 patients who died from melanoma
were divided into four groups (see Methods) with increasing risk of
death, as defined by the survival model. Subsequently, the risk
thresholds of the four groups were applied to all the patients. The
Kaplan-Meier estimates (step functions) and the predicted survival
curves (smooth curves) from the survival model are depicted for these
four groups. All four of the groups differed from each other significantly
(all p-values,0.001 in the log-rank test comparing group 2 to group 1,
group 3 to group 2, and group 4 to group 3).
doi:10.1371/journal.pmed.1001604.g007
Quantification of Melanoma Spread and Survival
PLOS Medicine | www.plosmedicine.org 15 February 2014 | Volume 11 | Issue 2 | e1001604
Table S1 DCCD in relation to standard prognostic
factors in 1,027 patients.
(DOCX)
Table S2 Observed and expected number of deaths for
three groups of patients at the time of follow-up for each
patient.
(DOCX)
Table S3 Goodness of fit of four multivariable survival
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Editors’ Summary
Background. Because the skin contains many different cell
types, there are many types of skin cancer. The most
dangerous type—melanoma—develops when mutations
occur in melanocytes, the cells that produce the pigment
melanin. Less than 5% of skin cancers are melanomas, but
melanoma causes most skin cancer deaths. Early signs of
melanoma are a change in the appearance of a mole (a
pigmented skin blemish) or the development of a new and
unusual pigmented lesion. If these signs are noticed and the
melanoma is diagnosed before it has spread from the skin
into nearby lymph nodes and other tissues, surgery often
provides a cure. For advanced melanomas, the outlook is
generally poor, although novel therapies may prolong a
patient’s life.
Why Was This Study Done? When a person is diagnosed
with melanoma, it is important to ‘‘stage’’ the tumor.
Knowing the extent and severity of the melanoma helps
oncologists plan treatments and estimate their patients’
likely outcomes. The detection of isolated melanoma cells in
sentinel lymph nodes (the nodes to which cancer cells are
most likely to spread from a primary tumor) is included in
melanoma staging recommendations. However, finding rare
tumor cells in sentinel lymph node biopsies by examining
the tissue requires the analysis of many slides from each
node removed from the patient and is extremely time-
consuming. In this study, the researchers investigate the
predictive value of a quantitative immunocytological assay
that involves disaggregation of the sentinel node and
detection of disseminated cancer cells (DCCs) by immuno-
staining for gp100 (a marker for melanoma cells). They also
use this new assay to examine the effect of increasing
numbers of DCCs on melanoma-specific survival.
What Did the Researchers Do and Find? The researchers
used routine histopathology and immunocytology to ana-
lyze 1,834 sentinel lymph nodes from 1,027 patients with
melanoma who underwent sentinel lymph node biopsy at
one German hospital. For immunocytology, the researchers
recorded the number of gp100-positive cells per million
lymph node cells (the DCC density). During follow-up, 138
patients (13.4%) died from melanoma. The results indicated
that increased DCC density was associated with an increased
risk of death due to melanoma. Specifically, every 10-fold
increase in DCC density + 1 was associated with a near
doubling of the risk of death from melanoma (a hazard ratio
of 1.81). Even patients with three or fewer gp100-positive
cells per million lymph node cells had an increased risk of
dying from melanoma compared to patients with no gp100-
positive cells (hazard ratio 1.63). When other predictors of
outcome such as age and primary tumor location were taken
into account, DCC density was a stronger predictor of death
than histopathology. Finally, a survival model that included
tumor thickness, tumor ulceration, and DCC density provided
survival prediction superior to that of a model based on the
current standard staging recommendations.
What Do These Findings Mean? These findings show
that quantification of cancer cell dissemination from mela-
nomas to sentinel lymph nodes is feasible and can be
combined with other characteristics of the primary tumor to
provide an accurate prediction of outcomes for individual
patients with melanoma. Notably, the new prediction model
identifies a group of patients at high risk of progression for
whom the current clinical standard underestimates the risk
of death. These patients may benefit from adjuvant
therapies, so the new analysis presented in this study may
help to stratify patients for clinical trials. Importantly,
quantitative immunocytology and the new model, although
internally validated in this study, need to be validated in an
independent group of patients before they can be consid-
ered for routine clinical use. If external validation is
successful, quantitative immunocytology, which is much less
labor-intensive than histopathology, has the potential to
change the routine clinical care of patients with melanoma
and probably with other solid tumors, conclude the
researchers.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001604.
N The US National Cancer Institute provides information for
patients and professionals on melanoma, cancer staging,
and sentinel lymph node biopsy (in English and Spanish)
N The nonprofit organization American Cancer Society
provides information in several languages on cancer and
how it develops and specific information on melanoma,
including the AJCC system for staging and personal stories
N The UK National Health Service Choices website includes
an introduction to cancer and a page on melanoma that
includes personal stories
N The nonprofit organization Cancer Research UK provides
basic information about cancer and detailed information
on melanoma
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